Tyra Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Tyra Biosciences, Inc. (TYRA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.73 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-04
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 2.45M shares, a 311.18% increase year-over-year.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 278.20K shares, a 36.00% decline year-over-year.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 3.14M shares, a 39.57% increase year-over-year.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was 595.40K shares, a 16.51% increase year-over-year.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 3.29M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 2.45M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 2.73M shares 10-Q · filed 2026-08-04 | ||
| 2026-03-31 | 278.20K shares 10-Q · filed 2026-05-13 | |||
| 2025-09-30 | 3.14M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 3.73M shares derived: sum of 2 quarters · filed 2025-11-05 | 4.17M shares 10-Q · filed 2025-11-05 | |
| 2025-06-30 | 595.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 1.03M shares 10-Q · filed 2025-08-14 | ||
| 2025-03-31 | 434.70K shares 10-Q · filed 2025-05-08 | |||
| 2024-09-30 | 2.25M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 2.76M shares derived: sum of 2 quarters · filed 2024-11-07 | 2.93M shares 10-Q · filed 2024-11-07 | |
| 2024-06-30 | 511.05K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 680.55K shares 10-Q · filed 2024-08-07 | ||
| 2024-03-31 | 169.50K shares 10-Q · filed 2024-05-09 | |||
| 2023-09-30 | 2.11M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 2.34M shares derived: sum of 2 quarters · filed 2023-11-07 | 2.88M shares 10-Q · filed 2023-11-07 | |
| 2023-06-30 | 235.65K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 776.95K shares 10-Q · filed 2023-08-10 | ||
| 2023-03-31 | 541.30K shares 10-Q · filed 2023-05-04 | |||
| 2022-09-30 | 1.76M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 2.44M shares derived: sum of 2 quarters · filed 2022-11-03 | 2.63M shares 10-Q · filed 2022-11-03 | 3.83M shares derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | 676.31K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 866.80K shares 10-Q · filed 2022-08-04 | 2.07M shares derived: sum of 3 quarters · filed 2022-08-04 | |
| 2022-03-31 | 190.49K shares 10-Q · filed 2022-05-05 | 1.39M shares derived: sum of 2 quarters · filed 2022-05-05 | ||
| 2021-12-31 | 1.20M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | 3.29M shares 10-K · filed 2022-03-03 | ||
| 2021-09-30 | 2.09M shares 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |